<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25889308</article-id><article-id pub-id-type="pmc">4445792</article-id><article-id pub-id-type="publisher-id">612</article-id><article-id pub-id-type="doi">10.1186/s13075-015-0612-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kremer</surname><given-names>Joel M</given-names></name><address><email>jkremer@joint-docs.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kivitz</surname><given-names>Alan J</given-names></name><address><email>ajkivitz@yahoo.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Simon-Campos</surname><given-names>Jesus A</given-names></name><address><email>jabrahamsimon@yahoo.com.mx</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Nasonov</surname><given-names>Evgeny L</given-names></name><address><email>nasonov@irramn.ru</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Tony</surname><given-names>Hans-Peter</given-names></name><address><email>Tony_H@ukw.de</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Soo-Kon</given-names></name><address><email>SOOKONLEE@yuhs.ac</email></address><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Vlahos</surname><given-names>Bonnie</given-names></name><address><email>bonnie.vlahos@pfizer.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Hammond</surname><given-names>Constance</given-names></name><address><email>connie.hammond@pfizer.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Bukowski</surname><given-names>Jack</given-names></name><address><email>JACK.BUKOWSKI@PFIZER.COM</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Huihua</given-names></name><address><email>Huihua.Li@pfizer.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Schulman</surname><given-names>Seth L</given-names></name><address><email>seth.schulman@pfizer.com</email></address><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Raber</surname><given-names>Susan</given-names></name><address><email>susan.raber@pfizer.com</email></address><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Zuckerman</surname><given-names>Andrea</given-names></name><address><email>andrea.zuckerman@pfizer.com</email></address><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Isaacs</surname><given-names>John D</given-names></name><address><email>John.Isaacs@newcastle.ac.uk</email></address><xref ref-type="aff" rid="Aff10"/></contrib><aff id="Aff1"><label/>Albany Medical College and The Center for Rheumatology, Albany, NY USA </aff><aff id="Aff2"><label/>Altoona Center for Clinical Research, Duncansville, PA USA </aff><aff id="Aff3"><label/>Hospital CEM/BIOCEM, Merida, Mexico </aff><aff id="Aff4"><label/>Nasonova State Institute of Rheumatology, Moscow, Russia </aff><aff id="Aff5"><label/>University Hospital W&#x000fc;rzburg, W&#x000fc;rzburg, Germany </aff><aff id="Aff6"><label/>Yonsei University College of Medicine, Seoul, South Korea </aff><aff id="Aff7"><label/>Pfizer Inc, Collegeville, PA USA </aff><aff id="Aff8"><label/>Pfizer Inc, San Diego, CA USA </aff><aff id="Aff9"><label/>Pfizer Inc, Groton, CT USA </aff><aff id="Aff10"><label/>National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle-upon-Tyne, UK </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>17</volume><issue>1</issue><elocation-id>95</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Kremer et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). During the clinical development programme, increases in mean serum creatinine (SCr) of approximately 0.07&#x000a0;mg/dL and 0.08&#x000a0;mg/dL were observed which plateaued early. This study assessed changes in measured glomerular filtration rate (mGFR) with tofacitinib relative to placebo in patients with active RA.</p></sec><sec><title>Methods</title><p>This was a randomised, placebo-controlled, Phase 1 study (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01484561">NCT01484561</ext-link>). Patients were aged &#x02265;18&#x000a0;years with active RA. Patients were randomised 2:1 to oral tofacitinib 10&#x000a0;mg twice daily (BID) in Period 1 then placebo BID in Period 2 (tofacitinib&#x02009;&#x02192;&#x02009;placebo); or oral placebo BID in both Periods (placebo&#x02009;&#x02192;&#x02009;placebo). Change in mGFR was evaluated by iohexol serum clearance at four time points (run-in, pre-dose in Period 1, Period 1 end, and Period 2 end). The primary endpoint was the change in mGFR from baseline to Period 1 end. Secondary endpoints included: change in mGFR at other time points; change in estimated GFR (eGFR; Cockcroft&#x02013;Gault equation) and SCr; efficacy; and safety.</p></sec><sec><title>Results</title><p>148 patients were randomised to tofacitinib&#x02009;&#x02192;&#x02009;placebo (N&#x02009;=&#x02009;97) or placebo&#x02009;&#x02192;&#x02009;placebo (N&#x02009;=&#x02009;51). Baseline characteristics were similar between groups. A reduction of 8% (90% confidence interval [CI]: 2%, 14%) from baseline in adjusted geometric mean mGFR was observed during tofacitinib treatment in Period 1 vs placebo. During Period 2, mean mGFR returned towards baseline during placebo treatment, and there was no difference between the two treatment groups at the end of the study &#x02013; ratio (tofacitinib&#x02009;&#x02192;&#x02009;placebo/placebo&#x02009;&#x02192;&#x02009;placebo) of adjusted geometric mean fold change of mGFR was 1.04 (90% CI: 0.97, 1.11). Post-hoc analyses, focussed on mGFR variability in placebo&#x02009;&#x02192;&#x02009;placebo patients, were consistent with this conclusion. At study end, similar results were observed for eGFR and SCr. Clinical efficacy and safety were consistent with prior studies.</p></sec><sec><title>Conclusion</title><p>Increases in mean SCr and decreases in eGFR in tofacitinib-treated patients with RA may occur in parallel with decreases in mean mGFR; mGFR returned towards baseline after tofacitinib discontinuation, with no significant difference vs placebo, even after post-hoc analyses. Safety monitoring will continue in ongoing and future clinical studies and routine pharmacovigilance.</p></sec><sec><title>Trial registration</title><p>Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01484561">NCT01484561</ext-link>. Registered 30 November 2011.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13075-015-0612-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). In six phase-3 randomised controlled trials, tofacitinib 5 and 10&#x000a0;mg twice daily (BID) as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs) were effective in reducing the signs and symptoms of RA, improving physical function, patient-reported outcomes, and structural preservation, and had a consistent safety profile [<xref ref-type="bibr" rid="CR1">1</xref>-<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Tofacitinib treatment in pooled RA phase-3 studies over 12&#x000a0;months resulted in mean increases from baseline in serum creatinine (SCr) levels [<xref ref-type="bibr" rid="CR7">7</xref>]. Increases occurred predominantly within the first 3&#x000a0;months. Mean SCr increases at month 3 were 0.07 and 0.08&#x000a0;mg/dL for tofacitinib 5- and 10-mg BID doses, respectively, compared with 0.04&#x000a0;mg/dL and 0.06&#x000a0;mg/dL in the placebo and adalimumab groups, respectively [<xref ref-type="bibr" rid="CR7">7</xref>]. Further analyses suggested that effects on mean SCr plateaued, remained within normal limits, were reversible and did not appear to be associated with acute renal failure (ARF) or progressive worsening of renal function in the long-term extension (LTE) studies [<xref ref-type="bibr" rid="CR7">7</xref>]. The mechanism behind these SCr changes with tofacitinib treatment is unknown; however, it may involve tofacitinib-induced changes in inflammation and creatine kinase [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>General toxicology preclinical investigations had demonstrated that tofacitinib was not nephrotoxic in rats and monkeys [<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref>]. In a placebo-controlled, healthy volunteer study, tofacitinib treatment (up to 15&#x000a0;mg BID for 14&#x000a0;days) had no effect on glomerular filtration rate (GFR), effective renal plasma flow or creatinine clearance [<xref ref-type="bibr" rid="CR10">10</xref>]. Additionally, based upon a study of metformin in healthy volunteers, tofacitinib does not appear to interfere with tubular transport of creatinine [<xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Within the literature, it is important to recognise that changes in SCr and measured GFR (mGFR) do not always correlate [<xref ref-type="bibr" rid="CR13">13</xref>-<xref ref-type="bibr" rid="CR16">16</xref>]. As SCr is derived from muscle creatine, many factors affect SCr independently of GFR and include, but are not limited to: age, gender, race, medications, diet, illness, muscle mass and muscle turnover [<xref ref-type="bibr" rid="CR13">13</xref>-<xref ref-type="bibr" rid="CR16">16</xref>]. Patients with RA have reduced physical activity and muscle mass, and present with various co-morbidities, as well as increased inflammation [<xref ref-type="bibr" rid="CR17">17</xref>-<xref ref-type="bibr" rid="CR20">20</xref>]. Indeed, a prior analysis showed that the greater the baseline C-reactive protein (CRP) and the greater the change in CRP with tofacitinib treatment, the greater the change in SCr [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, the interpretation of SCr levels is complex in this population, and these factors need to be taken into consideration when estimating GFR in patients with RA.</p><p>While no effect of tofacitinib on mGFR was seen in healthy volunteers, the interaction between inflammation and potential metabolic mechanisms influencing SCr suggests that measurement of GFR in patients with RA is necessary to fully understand the impact of tofacitinib on renal function. Therefore, the objectives of this study were to determine whether tofacitinib induced changes in mGFR relative to placebo in this population of patients with active RA, and the extent to which these changes, if any, were reversible after discontinuation of tofacitinib treatment.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>Eligible participants were &#x02265;18&#x000a0;years of age with a diagnosis of RA based on the American College of Rheumatology (ACR) 1987 Revised Criteria for Classification of RA [<xref ref-type="bibr" rid="CR21">21</xref>]. Patients must have had an inadequate response to at least one DMARD (non-biologic or biologic) due to lack of efficacy or intolerance. Other key inclusion criteria included active RA defined by &#x02265;4 tender/painful joints and &#x02265;4 swollen joints, and either erythrocyte sedimentation rate (Westergren method) &#x0003e;28&#x000a0;mm/h or CRP &#x0003e;7&#x000a0;mg/L. Patients were excluded if they had an estimated GFR (eGFR) &#x0003c;40&#x000a0;mL/min (Cockcroft-Gault calculation).</p><p>Biologic DMARDs, potent immunosuppressive agents (for example, cyclosporine, azathioprine), injectable gold, penicillamine, intravenous (IV), intramuscular and intra-articular corticosteroids were prohibited. The patient was permitted (but was not required) to continue on background non-biologic DMARDs.</p></sec><sec id="Sec4"><title>Study design</title><p>This was a phase-1, randomised, placebo-controlled, parallel-group, two-period study (A3921152; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT01484561">NCT01484561</ext-link>). The study was conducted at 23 study centres (one in the Czech Republic, Korea and Mexico; three in Germany; four in Poland, Russia and Spain; five in the USA). There were two study centres in Germany that received the study drug, but did not randomise patients. Patients were randomised 2:1 to one of two fixed sequences, each consisting of two study periods: patients received oral tofacitinib 10&#x000a0;mg BID in period 1 and oral placebo BID in period 2 (tofacitinib&#x02009;&#x02192;&#x02009;placebo) or patients received oral placebo BID in periods 1 and 2 (placebo&#x02009;&#x02192;&#x02009;placebo). Randomisation was achieved using an interactive voice response system - an automated web/telephone randomisation system containing the randomisation schedule. Protocol amendments are listed in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p><p>Data from phase-2 and phase-3 studies suggested a greater increase in SCr with the tofacitinib 10-mg BID dose versus the tofacitinib 5-mg BID dose; therefore, in order to increase the probability of observing any potential effects on mGFR, the tofacitinib 10-mg BID dose was selected for investigation in this study. From population modelling analysis of the phase-2 study results, steady-state SCr increases were predicted to be achieved in approximately 6&#x000a0;weeks in a typical patient with RA. Therefore, the duration of tofacitinib treatment in this study was chosen to be 6&#x000a0;weeks (through day 43 in period 1). In a phase-2 study, modelling analysis predicted that after cessation of tofacitinib administration, the 90% upper confidence limit of the mean increase in SCr fell below 10% of pre-treatment baseline within 2 to 6&#x000a0;weeks. Therefore, to evaluate reversibility of the increase in SCr in this study, renal function was to be evaluated 4&#x000a0;weeks after the end of tofacitinib treatment (day 29 in period 2). The selection of the tofacitinib 10-mg BID dose was based on the prior phase-2 and phase-3 studies of tofacitinib in RA.</p><p>In period 1, patients received the study drug (tofacitinib or placebo) in the evening of day 1 through to at least the morning of day 43 (up to the morning of day 50). Period 2 immediately followed the end of period 1. In period 2, patients received placebo BID in the evening of day 1 through to at least the morning of day 29 (up to the morning of day 36). In period 1, the patient, the investigator, the site staff and the sponsor were blinded to individual patients&#x02019; treatment assignment. In period 2, only patients remained blinded. For the duration of the study, the patients, investigator, the site staff and sponsor remained blinded to the assigned treatment sequence. The approximate total duration of treatment with study drug (tofacitinib or placebo) in periods 1 and 2 was at least 10&#x000a0;weeks (up to 12&#x000a0;weeks). Patients who completed at least period 1 through day 43 in this study were given the option (if they were eligible for enrollment) to enrol in an open-label LTE study A3921024 (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00413699">NCT00413699</ext-link>).</p><p>The study was conducted in compliance with the provisions of the Declaration of Helsinki Good Clinical Practice guidelines of the International Conference on Harmonisation and relevant local country regulations. All patients provided written informed consent. The final protocol, amendments and consent documentation were reviewed and approved by the Institutional Review Board and/or Independent Ethics Committee at each participating centre (Additional file <xref rid="MOESM1" ref-type="media">1</xref>).</p></sec><sec id="Sec5"><title>Study endpoints and assessments</title><p>The study was exploratory in nature and was designed with a primary objective of estimating the ratio (tofacitinib&#x02009;&#x02192;&#x02009;placebo/placebo&#x02009;&#x02192;&#x02009;placebo) in the adjusted geometric mean fold-change of mGFR from baseline to period 1 end. Secondary endpoints included: change in mGFR following tofacitinib withdrawal; changes in eGFR (Cockcroft-Gault equation) and SCr with tofacitinib treatment relative to placebo, and evaluation of the efficacy and safety of tofacitinib in patients with active RA.</p><p>Each patient underwent mGFR evaluations by determining iohexol serum clearance at four pre-scheduled time points: during the run-in period (between day 14 and day 2), pre-dose on day 1 of period 1, post-dose on the last day of period 1 and post-dose on the last day of period 2. Additionally, SCr levels were obtained at screening, pre-dose on day 1 of period 1, and on the last day of period 1 and of period 2. eGFR was calculated (using the Cockcroft-Gault equation) at both screening and pre-dose on day 1 of period 1 by the site, then at all visits during treatment with the study drug by the sponsor. Iohexol serum clearance was determined after an IV bolus injection of non-radioactive iohexol followed by serial blood sampling. Further details on the iohexol serum clearance procedure can be found in Additional file <xref rid="MOESM1" ref-type="media">1</xref>.</p><p>Efficacy was assessed by ACR response rates of 20%, 50% and 70% (ACR20/50/70); disease activity score in 28 joints (DAS28)-3(CRP)/DAS28-4(CRP); and their components. The incidence and severity of all adverse events (AEs) were recorded; clinical laboratory tests, vital signs and physical examinations were performed at scheduled visits.</p></sec><sec id="Sec6"><title>Statistical analyses</title><p>Details on sample size determination can be found in Additional file <xref rid="MOESM1" ref-type="media">1</xref>. Statistical analyses focused on point estimations and confidence intervals (CIs). No formal hypothesis test was performed; <italic>P</italic>-values are considered descriptive statistics. All analyses were performed on the full analysis set (FAS) unless otherwise stated &#x02013; defined as all randomised patients who received &#x02265;1 dose of study drug (tofacitinib or placebo). Additionally, analysis of GFR data was performed on the per-protocol analysis set (PPAS) - defined as a subset of patients in the FAS, who completed the treatment period and who had no major protocol deviations that may impact renal function assessments.</p><p>mGFR was determined as iohexol serum clearance using a non-linear mixed-effects modelling approach (NONMEM version 7.2) of the iohexol serum concentration-time data. Serial blood sample collection was designed to maximise precision of the estimate, assuming a two-compartment model based on a prior study and literature reports [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref>]. Iohexol clearance values were also normalised by body surface area.</p><p>Baseline mGFR was calculated as the mean of the values obtained in the run-in period and pre-dose on day 1 of period 1. Following natural log transformation, an analysis of covariance (ANCOVA) model was used to analyse the mGFR change from baseline with treatment and baseline mGFR (natural log-transformed) as covariates. For change from period 1 end to period 2 end, the ANCOVA model included treatment and the mGFR collected at period 1 end (on log scale) as covariates. The treatment difference and two-sided 90% CI on the log-transformed scale were then back-transformed to derive the treatment ratios for the geometric mean fold-changes. Additional sensitivity analysis using a linear mixed-effects model was performed with mGFR value (on log scale) as a response variable, treatment group, visit and treatment group by visit interaction as fixed effects and patients as random effect. The eGFR and SCr data were analysed in a similar manner.</p><p>To assess the robustness of our findings on the mGFR changes, post-hoc ANCOVA was performed to exclude patients who had an outlier mGFR result. An outlier mGFR result was defined as the difference between mGFR and eGFR falling outside the 95% limits of agreement between the two methods of measurement. Distribution of mGFR changes were graphically examined using box and whisker plots.</p><p>For ACR variables, the normal approximation for the difference in the binomial proportions was performed at the end of each period. Response rate was calculated for the data as is (no imputation) and using the last observation carried forward for skipped components and the non-responder imputation after early withdrawals.</p><p>DAS28-3(CRP)/DAS28-4(CRP) was expressed as change from baseline. The analysis was done using the ANCOVA model including treatment and baseline as covariate. The endpoint was also analysed by a linear mixed-effects model with actual value as a response variable, treatment group, visit and treatment group by visit interaction as fixed effects and patients as random effect.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Patients</title><p>A total of 148 patients were randomised to treatment (tofacitinib&#x02009;&#x02192;&#x02009;placebo, N&#x02009;=&#x02009;97; placebo&#x02009;&#x02192;&#x02009;placebo, N&#x02009;=&#x02009;51) and received at least one dose of study medication. Of these, 133 patients (89.9%) completed the study (tofacitinib&#x02009;&#x02192;&#x02009;placebo, N&#x02009;=&#x02009;88; placebo&#x02009;&#x02192;&#x02009;placebo, N&#x02009;=&#x02009;45). All 148 patients were included in the FAS and were evaluated for safety. Patient disposition is summarised in Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>Consolidated standards of reporting trials (CONSORT) diagram.</p></caption><graphic xlink:href="13075_2015_612_Fig1_HTML" id="MO1"/></fig></p><p>The majority of patients were female (75.0%) and white (93.9%), with a mean age of 50.3&#x000a0;years (range 22 to 77&#x000a0;years). RA disease duration ranged from 0.3 to 37&#x000a0;years. Patient demographics and baseline characteristics are summarised in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Summary of baseline demographics and disease characteristics (full analysis set)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>
<bold>Characteristic</bold>
</th><th>
<bold>Tofacitinib</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Placebo</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th></tr><tr valign="top"><th/><th>
<bold>(N&#x02009;=&#x02009;97)</bold>
</th><th>
<bold>(N&#x02009;=&#x02009;51)</bold>
</th></tr></thead><tbody><tr><td>Mean (SD) age, years</td><td>51.86 (12.68)</td><td>47.25 (11.84)</td></tr><tr valign="top"><td>Sex, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Male</td><td>22 (22.7)</td><td>15 (29.4)</td></tr><tr valign="top"><td>&#x02003;Female</td><td>75 (77.3)</td><td>36 (70.6)</td></tr><tr valign="top"><td>Race, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;White</td><td>90 (92.8)</td><td>49 (96.1)</td></tr><tr valign="top"><td>&#x02003;Asian</td><td>3 (3.1)</td><td>1 (2.0)</td></tr><tr valign="top"><td>&#x02003;Black</td><td>3 (3.1)</td><td>0</td></tr><tr valign="top"><td>&#x02003;Other</td><td>1 (1.0)</td><td>1 (2.0)</td></tr><tr valign="top"><td>Mean (SD) body mass index, kg/m<sup>2</sup>
</td><td>28.71 (6.16)</td><td>28.11 (7.13)</td></tr><tr valign="top"><td>Mean (SD) duration of rheumatoid arthritis</td><td>8.67 (7.49)</td><td>8.25 (7.94)</td></tr><tr valign="top"><td>Prior corticosteroid use, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Yes</td><td>50 (51.5)</td><td>21 (41.2)</td></tr><tr valign="top"><td>&#x02003;No</td><td>47 (48.5)</td><td>30 (58.8)</td></tr><tr valign="top"><td>Prior DMARD use, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Yes</td><td>94 (96.9)</td><td>47 (92.2)</td></tr><tr valign="top"><td>&#x02003;No</td><td>3 (3.1)</td><td>4 (7.8)</td></tr><tr valign="top"><td>Prior NSAID use, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Yes</td><td>73 (75.3)</td><td>35 (68.6)</td></tr><tr valign="top"><td>&#x02003;No</td><td>24 (24.7)</td><td>16 (31.4)</td></tr><tr valign="top"><td>Prior methotrexate use, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Yes</td><td>87 (89.7)</td><td>47 (92.2)</td></tr><tr valign="top"><td>&#x02003;No</td><td>10 (10.3)</td><td>4 (7.8)</td></tr><tr valign="top"><td>Mean (SD) erythrocyte sedimentation rate, mm/h</td><td>45.34 (17.43)</td><td>47.08 (23.83)</td></tr><tr valign="top"><td>Mean (SD) C-reactive protein, mg/L</td><td>18.37 (22.57)</td><td>15.66 (22.55)</td></tr><tr valign="top"><td>Rheumatoid factor, n (%)</td><td/><td/></tr><tr valign="top"><td>&#x02003;Positive</td><td>69 (71.1)</td><td>34 (66.7)</td></tr><tr valign="top"><td>&#x02003;Negative</td><td>28 (28.9)</td><td>17 (33.3)</td></tr><tr valign="top"><td>Mean (SD) DAS28-3(CRP)</td><td>5.27 (0.95)</td><td>5.31 (0.81)</td></tr><tr valign="top"><td>Mean (SD) DAS28-4(CRP)</td><td>5.50 (1.05)</td><td>5.56 (0.93)</td></tr><tr valign="top"><td>Mean (SD) Patient Assessment of Arthritis Pain</td><td>53.98 (22.77)</td><td>57.45 (21.04)</td></tr><tr valign="top"><td>Mean (SD) Patient Global Assessment of Arthritis</td><td>56.13 (23.78)</td><td>58.67 (21.70)</td></tr><tr valign="top"><td>Mean (SD) Physician Global Assessment of Arthritis</td><td>57.24 (17.83)</td><td>55.22 (17.11)</td></tr><tr valign="top"><td>Mean (SD) tender/painful joint counts</td><td>20.41 (11.63)</td><td>23.43 (13.34)</td></tr><tr valign="top"><td>Mean (SD) swollen joint counts</td><td>12.48 (6.76)</td><td>12.67 (6.91)</td></tr><tr valign="top"><td>Mean (SD) HAQ-DI</td><td>1.49 (0.65)</td><td>1.41 (0.69)</td></tr></tbody></table><table-wrap-foot><p>DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ-DI, health assessment questionnaire-disability index; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Renal endpoints</title><sec id="Sec10"><title>mGFR</title><p>Baseline mGFR was comparable between the two treatment groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the tofacitinib&#x02009;&#x02192;&#x02009;placebo group, median mGFR decreased by 6.46&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> from baseline to period 1 end (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Following tofacitinib withdrawal in period 2, median mGFR increased by 1.68&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> compared with period 1. In the placebo&#x02009;&#x02192;&#x02009;placebo group, there was little change in mGFR at period 1 end; however, at the end of period 2, median mGFR decreased by 3.25&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Overall, at period 2 end compared with baseline, median mGFR decreased by 3.41&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> in the tofacitinib&#x02009;&#x02192;&#x02009;placebo group and by 3.88&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup> in the placebo&#x02009;&#x02192;&#x02009;placebo group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Descriptive statistics of change in mGFR, eGFR (Cockcroft-Gault) and serum creatinine (full analysis set)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">
<bold>mGFR (mL/min/1.73&#x000a0;m</bold>
<sup><bold>2</bold></sup>
<bold>)</bold>
</th><th colspan="2">
<bold>eGFR (Cockcroft-Gault) (mL/min/1.73&#x000a0;m</bold>
<sup><bold>2</bold></sup>
<bold>)</bold>
</th><th colspan="2">
<bold>Serum creatinine (mg/dL)</bold>
</th></tr><tr valign="top"><th/><th>
<bold>Tofacitinib</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Placebo</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Tofacitinib</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Placebo</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Tofacitinib</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Placebo</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th></tr></thead><tbody><tr><td colspan="7">
<bold>Baseline</bold>
</td></tr><tr valign="top"><td>&#x02003;Number</td><td>97</td><td>51</td><td>97</td><td>51</td><td>97</td><td>51</td></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>88.98 (18.79)</td><td>89.67 (21.33)</td><td>104.19 (28.42)</td><td>111.30 (26.91)</td><td>0.77 (0.15)</td><td>0.76 (0.17)</td></tr><tr valign="top"><td>&#x02003;Median (Q1, Q3)</td><td>87.98 (75.76, 99.98)</td><td>86.99 (75.17, 98.20)</td><td>97.22 (82.43, 125.57)</td><td>107.22 (91.47, 134.89)</td><td>0.76 (0.67, 0.85)</td><td>0.75 (0.64, 0.84)</td></tr><tr valign="top"><td colspan="7">
<bold>Change at end of period 1 from baseline</bold>
</td></tr><tr valign="top"><td>&#x02003;Number</td><td>91</td><td>46</td><td>92</td><td>46</td><td>92</td><td>46</td></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>&#x02212;6.73 (16.44)</td><td>&#x02212;0.50 (17.34)</td><td>&#x02212;3.59 (10.31)</td><td>1.28 (11.48)</td><td>0.03 (0.07)</td><td>&#x02212;0.00 (0.07)</td></tr><tr valign="top"><td>&#x02003;Median (Q1, Q3)</td><td>&#x02212;6.46 (&#x02212;11.85, 2.14)</td><td>0.82 (&#x02212;5.48, 6.79)</td><td>&#x02212;3.36 (&#x02212;9.18, 2.86)</td><td>2.30 (&#x02212;5.71, 6.14)</td><td>0.02 (&#x02212;0.02, 0.08)</td><td>&#x02212;0.01 (&#x02212;0.05, 0.04)</td></tr><tr valign="top"><td colspan="7">
<bold>Change at end of period 2 from baseline</bold>
</td></tr><tr valign="top"><td>&#x02003;Number</td><td>86</td><td>45</td><td>87</td><td>44</td><td>87</td><td>44</td></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>&#x02212;3.02 (17.55)</td><td>&#x02212;5.96 (20.66)</td><td>0.03 (10.15)</td><td>0.48 (9.54)</td><td>0.00 (0.07)</td><td>&#x02212;0.00 (0.05)</td></tr><tr valign="top"><td>&#x02003;Median (Q1, Q3)</td><td>&#x02212;3.41 (&#x02212;8.55, 3.65)</td><td>&#x02212;3.88 (&#x02212;9.13, 7.58)</td><td>&#x02212;0.32 (&#x02212;6.05, 5.74)</td><td>0.18 (&#x02212;3.81, 4.28)</td><td>0.00 (&#x02212;0.05, 0.05)</td><td>0.00 (&#x02212;0.03, 0.03)</td></tr><tr valign="top"><td colspan="7">
<bold>Change at end of period 2 from end of period 1</bold>
</td></tr><tr valign="top"><td>&#x02003;Number</td><td>86</td><td>45</td><td>87</td><td>44</td><td>87</td><td>44</td></tr><tr valign="top"><td>&#x02003;Mean (SD)</td><td>2.92 (19.02)</td><td>&#x02212;5.41 (16.65)</td><td>3.71 (11.95)</td><td>&#x02212;0.97 (10.06)</td><td>&#x02212;0.03 (0.08)</td><td>0.00 (0.07)</td></tr><tr valign="top"><td>&#x02003;Median (Q1, Q3)</td><td>1.68 (&#x02212;3.60, 8.62)</td><td>&#x02212;3.25 (&#x02212;12.24, 2.29)</td><td>2.94 (&#x02212;4.45, 10.31)</td><td>&#x02212;2.07 (&#x02212;7.29, 6.09)</td><td>&#x02212;0.02 (&#x02212;0.07, 0.03)</td><td>0.01 (&#x02212;0.04, 0.05)</td></tr></tbody></table><table-wrap-foot><p>eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation.</p></table-wrap-foot></table-wrap></p><p>Tofacitinib treatment in period 1 was associated with a reduction of 8% (90% CI: 2%, 14%) from baseline in adjusted geometric mean mGFR versus placebo. The reduction in geometric mean mGFR associated with tofacitinib in period 1 reversed during placebo treatment in period 2, and there was no statistically significant difference between the two treatment groups at the end of the study (ratio 1.04; 90% CI: 0.97, 1.11). The geometric mean fold-change in mGFR from baseline to the end of period 1 and period 2 is shown in Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A. The sensitivity analysis results (the linear mixed-effects model on the FAS and ANCOVA from the PPAS) were comparable with the ANCOVA (FAS, observed case) analysis results.<fig id="Fig2"><label>Figure 2</label><caption><p>Adjusted geometric mean fold-change from baseline (90% CI) in measured glomerular filtration rate (mGFR) (A), estimated GFR (eGFR) (B) and serum creatinine (SCr) (C) (full analysis set, analysis of covariance, observed case).</p></caption><graphic xlink:href="13075_2015_612_Fig2_HTML" id="MO2"/></fig></p><p>Given the unexpected decline in mGFR in the placebo&#x02009;&#x02192;&#x02009;placebo group in period 2, as well as the observation of outliers (high or low mGFR values that did not appear to correspond to SCr or eGFR for a given patient), a post-hoc analysis was performed after excluding the outlier patients (15 patients in the tofacitinib&#x02009;&#x02192;&#x02009;placebo group and 9 patients in the placebo&#x02009;&#x02192;&#x02009;placebo group). The results of the post-hoc analysis were consistent with results for the primary analyses but the significant decline in mGFR in period 2 for the placebo&#x02009;&#x02192;&#x02009;placebo group was no longer apparent (geometric mean fold-change from baseline 0.98; 90% CI: 0.94, 1.01) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). A review of the outlier patients revealed no consistent demographic factors or concomitant medications, other than commonality of study centres.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Post-hoc analysis of mGFR change by excluding patients who had an outlier mGFR result (ANCOVA)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">
<bold>mGFR (mL/min/1.73&#x000a0;m</bold>
<sup><bold>2</bold></sup>
<bold>)</bold>
</th></tr><tr valign="top"><th/><th>
<bold>Tofacitinib</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th><th>
<bold>Placebo</bold>&#x02009;&#x02192;&#x02009;<bold>placebo group</bold>
</th></tr></thead><tbody><tr><td colspan="3">
<bold>Change at end of period 1 from baseline</bold>
</td></tr><tr valign="top"><td>Number</td><td>76</td><td>37</td></tr><tr valign="top"><td>Adjusted geometric mean fold-change (90% CI)</td><td>0.91 (0.88, 0.93)</td><td>1.01 (0.97, 1.04)</td></tr><tr valign="top"><td>Ratio of adjusted geometric mean fold-change (90% CI)</td><td align="center" colspan="2">0.90 (0.86, 0.94)</td></tr><tr valign="top"><td colspan="3">
<bold>Change at end of period 2 from baseline</bold>
</td></tr><tr valign="top"><td>Number</td><td>72</td><td>36</td></tr><tr valign="top"><td>Adjusted geometric mean fold-change (90% CI)</td><td>0.96 (0.93, 0.99)</td><td>0.98 (0.94, 1.01)</td></tr><tr valign="top"><td>Ratio of adjusted geometric mean fold-change (90% CI)</td><td align="center" colspan="2">0.98 (0.94, 1.03)</td></tr><tr valign="top"><td colspan="3">
<bold>Change at end of period 2 from end of period 1</bold>
</td></tr><tr valign="top"><td>Number</td><td>72</td><td>36</td></tr><tr valign="top"><td>Adjusted geometric mean fold-change (90% CI)</td><td>1.06 (1.03, 1.09)</td><td>0.99 (0.95, 1.03)</td></tr><tr valign="top"><td>Ratio of adjusted geometric mean fold-change (90% CI)</td><td align="center" colspan="2">1.07 (1.02, 1.12)</td></tr></tbody></table><table-wrap-foot><p>Post-hoc analysis excluded those patients with a difference between mGFR and eGFR falling outside the 95% limits of agreement between the two methods of measurement. ANCOVA, analysis of covariance; eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate.</p></table-wrap-foot></table-wrap></p><p>To more fully understand the variability in mGFR changes at the end of period 1 from baseline, an additional analysis of patients with greatest changes from the mean (defined by changes more than 1.5-times an interquartile distance from the upper and lower quartiles from the box plots (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>)) was undertaken. Similar proportions in each treatment group fell into this category (six (6.6%) tofacitinib&#x02009;&#x02192;&#x02009;placebo and three (6.5%) placebo&#x02009;&#x02192;&#x02009;placebo patients). Of these, four tofacitinib&#x02009;&#x02192;&#x02009;placebo and two placebo&#x02009;&#x02192;&#x02009;placebo patients had decreases from baseline (mean of run-in and pre-dose day 1 mGFR measurements), and two tofacitinib&#x02009;&#x02192;&#x02009;placebo patients and one placebo&#x02009;&#x02192;&#x02009;placebo patient had increases from baseline in mGFR. In this analysis, mGFR measurements at the end of period 1 were similar to one of the components of the baseline for two patients. Additionally, mGFR tended to revert to a value within the range of the component baseline values at the end of period 2 for six patients. Increases in SCr were generally &#x0003c;0.06&#x000a0;mg/dL for this group of patients (maximum SCr changes of 0.12 and 0.13&#x000a0;mg/dL for the tofacitinib&#x02009;&#x02192;&#x02009;placebo and placebo&#x02009;&#x02192;&#x02009;placebo groups, respectively). Discontinuations (one patient for lack of efficacy and one patient for bronchopneumonia) occurred at least 15&#x000a0;days into period 2.<fig id="Fig3"><label>Figure 3</label><caption><p>Box and whisker plot of change in measured glomerular filtration rate (mGFR) (full analysis set).</p></caption><graphic xlink:href="13075_2015_612_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>eGFR (Cockcroft-Gault)</title><p>Baseline eGFR was comparable between the two treatment groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the tofacitinib&#x02009;&#x02192;&#x02009;placebo group, median eGFR decreased from baseline to period 1 end and then increased following tofacitinib withdrawal in period 2 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Overall, the median eGFR at period 2 end was similar compared with baseline (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In the placebo&#x02009;&#x02192;&#x02009;placebo group, there was very little change in median eGFR between the three time points (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>At period 1 end, there was a 5% (90% CI: 2%, 8%) reduction from baseline in geometric mean eGFR associated with tofacitinib treatment versus placebo, which fully reversed during period 2 (geometric mean fold-change from end of period 1 to end of period 2, 1.03; 90% CI: 1.01, 1.05) and there was no difference between the two treatment groups at period 2 end (ratio 0.99; 90% CI: 0.97, 1.02) (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). Unlike the mGFR, there was no change in the placebo&#x02009;&#x02192;&#x02009;placebo group in either period 1 (geometric mean fold-change from baseline 1.01; 90% CI: 0.99, 1.04) or period 2 (geometric mean fold-change from end of period 1 to end of period 2, 1.00; 90% CI: 0.97, 1.02).</p></sec><sec id="Sec12"><title>Serum creatinine</title><p>Baseline SCr was comparable between the two treatment groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). At period 1 end there was a 5% (90% CI: 2%, 8%) increase from baseline in geometric mean SCr associated with tofacitinib treatment versus placebo. This SCr increase reversed during placebo treatment in period 2, and at period 2 end the treatment ratio was 1.01 (90% CI: 0.98, 1.04) (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). No change was observed in SCr at the end of period 2 versus the end of period 1 for the placebo&#x02009;&#x02192;&#x02009;placebo group.</p></sec></sec><sec id="Sec13"><title>Efficacy endpoints</title><p>Patients receiving tofacitinib reported significantly greater improvements versus placebo in the efficacy endpoints measured, namely, ACR20/50/70 response rates, and least squares mean changes from baseline in DAS28-3(CRP) and DAS28-4(CRP).</p></sec><sec id="Sec14"><title>Safety</title><p>Treatment-emergent AEs (TEAEs) were reported in 42 and 26 patients in the tofacitinib&#x02009;&#x02192;&#x02009;placebo and placebo&#x02009;&#x02192;&#x02009;placebo groups, respectively. The majority of AEs were mild or moderate in intensity. The most frequently reported TEAEs were nasopharyngitis (n&#x02009;=&#x02009;8 and n&#x02009;=&#x02009;3), headache (n&#x02009;=&#x02009;6 and n&#x02009;=&#x02009;1), nausea (n&#x02009;=&#x02009;5 and n&#x02009;=&#x02009;2) and urinary tract infection (n&#x02009;=&#x02009;3 and n&#x02009;=&#x02009;2) in the tofacitinib&#x02009;&#x02192;&#x02009;placebo and placebo&#x02009;&#x02192;&#x02009;placebo groups, respectively.</p><p>One tofacitinib&#x02009;&#x02192;&#x02009;placebo patient permanently discontinued during the placebo treatment period due to a serious AE (SAE) of bronchopneumonia. Four placebo&#x02009;&#x02192;&#x02009;placebo patients experienced AEs resulting in permanent discontinuation: increased SCr (Additional file <xref rid="MOESM1" ref-type="media">1</xref>), somnolence, lymphopaenia and urticaria. Seven and zero patients temporarily discontinued their study drug or temporarily reduced their dose due to AEs in the tofacitinib&#x02009;&#x02192;&#x02009;placebo and placebo&#x02009;&#x02192;&#x02009;placebo groups, respectively; none of the AEs were serious. With the exception of an AE of pharyngitis, all AEs leading to temporary discontinuation or dose reduction occurred during period 1.</p><p>Two SAEs (pelvic fracture and bronchopneumonia) out of 97 patients occurred during period 2 in two tofacitinib&#x02009;&#x02192;&#x02009;placebo patients. None of the 51 placebo&#x02009;&#x02192;&#x02009;placebo patients had an SAE at any time. No patients experienced an AE coded to the narrow standardised MedDRA (Medical Dictionary for Regulatory Activities) query of ARF (including preferred terms of acute phosphate nephropathy, acute pre-renal failure, anuria, azotemia, continuous haemodiafiltration, dialysis, haemodialysis, nephropathy toxic, oliguria, peritoneal dialysis, renal failure, renal impairment). There were no deaths reported in this study.</p><p>No trends in clinically important treatment-related changes in vital signs, electrocardiogram or laboratory abnormalities were observed.</p></sec></sec><sec id="Sec15" sec-type="discussion"><title>Discussion</title><p>The results of this study suggest that mean increases in SCr and mean decreases in eGFR in patients with active RA treated with tofacitinib 10&#x000a0;mg BID occur in parallel with decreases in mGFR. Furthermore, these changes were reversible following withdrawal of tofacitinib 10-mg BID treatment; although mean mGFR did not return completely to baseline, there was no significant difference between tofacitinib and placebo groups at the end of the study. While this conclusion is complicated by the unexpected observations in the placebo&#x02009;&#x02192;&#x02009;placebo group in period 2, it is further supported by the post-hoc analyses where the significant decline in the placebo&#x02009;&#x02192;&#x02009;placebo group during period 2 was no longer evident. The mean changes in SCr and eGFR observed in this study are similar to those reported in phase-2 and phase-3 RA studies of tofacitinib.</p><p>An unexpected finding was a decrease in mean and median mGFR during the second period in placebo&#x02009;&#x02192;&#x02009;placebo patients; as no concomitant changes in SCr were seen (the CIs for SCr changes were also much smaller than for mGFR), the interpretation and significance of the change in mGFR in the placebo&#x02009;&#x02192;&#x02009;placebo group during this period remains unclear. Given the variability in mGFR and not in SCr, as well as the lack of agreement between the measurements for mGFR and SCr, it is likely that these unexpected findings in mGFR reflect measurement methodology issues rather than significant changes in GFR. Several studies have shown iohexol serum clearance to be highly correlated with the renal clearance of inulin, the gold standard of GFR measurement [<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR24">24</xref>-<xref ref-type="bibr" rid="CR27">27</xref>]; however, variability in mGFR measurements is expected given the inherently technical and complex nature of the iohexol serum clearance procedure [<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR28">28</xref>]. This study required frequent and numerous timed blood samples to be collected and processed during four separate study visits in which the iohexol procedure was performed. Additionally, the procedure was conducted at multiple, global rheumatology study centres, rather than in a single clinical research unit, where patient diet, hydration and exercise could not be as rigidly controlled. Nonetheless, the variability observed in this study was consistent with the assumed variability used in the sample size calculation during protocol development and was within the range from previously published studies [<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref>]. A decline in mGFR was also observed in placebo subjects in an earlier study investigating the effect of tofacitinib on renal function in healthy adult volunteers, hence, the importance of including a placebo group in the current mGFR study [<xref ref-type="bibr" rid="CR10">10</xref>]. Post-hoc analyses were performed that excluded any mGFR outliers &#x02013; those patients with likely aberrant mGFR results based on large discrepancies in mGFR and eGFR measurements. In the outlier analyses, the decline observed during period 2 for the primary analysis in the placebo&#x02009;&#x02192;&#x02009;placebo group was not observed; however, the conclusions of the primary analyses that there was no significant difference in mGFR between tofacitinib and placebo groups at the end of the study was preserved. Therefore, despite the variability and potential technical limitations of the methodology, the study still detected a mean change in mGFR in patients with RA receiving tofacitinib.</p><p>Data on mGFR in patients with RA are limited. Changes in SCr and mGFR were not seen in a study of healthy volunteers dosed with tofacitinib, although study size and duration differences may not allow statements of differential effects in a specific population [<xref ref-type="bibr" rid="CR10">10</xref>]. This study was not designed to address mechanisms for potential effects of tofacitinib on SCr or mGFR nor the relative impacts of inflammation and GFR changes on SCr; however, the reversibility of the effect, at least after short-term treatment, is reassuring, and supports the results of the SCr analyses across phase-2, phase-3 and LTE studies of tofacitinib in patients with RA [<xref ref-type="bibr" rid="CR7">7</xref>]. In those studies, the relationship to baseline inflammation and its reduction, as well as to serum creatine kinase, suggests additional mechanisms may contribute to rises in SCr in patients receiving tofacitinib.</p><p>When applying to clinical practice, the changes in SCr and mGFR in tofacitinib-treated patients with RA should also be considered in the context of the concomitant medications received and the doses of such medications. It is unlikely that such changes in mGFR and SCr of the magnitude observed in this study will be clinically meaningful in the vast majority of patients; however, clinical judgement should be used when assessing changes in SCr or mGFR in patients with RA receiving tofacitinib. Data derived from a follow-up of patients on tofacitinib for up to 5&#x000a0;years in an LTE study do not suggest increased rates of renal AEs or progressive increases in levels of SCr [<xref ref-type="bibr" rid="CR31">31</xref>], but ongoing assessment will further address long-term consequences.</p></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusions</title><p>In summary, despite some potential operational limitations and technical challenges associated with the measurement of mGFR, the results of this study suggest that increases in SCr and decreases in eGFR in patients with RA treated with tofacitinib may reflect decreases in mGFR. Furthermore, changes in these parameters with short-term tofacitinib treatment appear reversible after discontinuation &#x02013; mGFR returned towards baseline, with no significant difference from placebo at the end of the study, even after post-hoc analyses where the decline in mGFR in placebo&#x02009;&#x02192;&#x02009;placebo patients was no longer present. The mechanisms behind these changes in renal endpoints are unknown. The overall safety and efficacy profiles were consistent with that of previous studies; safety monitoring will continue in ongoing and future clinical studies and routine pharmacovigilance to further assess the long-term and real-world renal safety profile of tofacitinib.</p></sec></body><back><app-group><app id="App1"><sec id="Sec17"><title>Additional file</title><p><media position="anchor" xlink:href="13075_2015_612_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Additional information, data and institutional review boards that are referred to within the main manuscript file.</bold>
</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>ACR</term><def><p>American College of Rheumatology</p></def></def-item><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>ANCOVA</term><def><p>analysis of covariance</p></def></def-item><def-item><term>ARF</term><def><p>acute renal failure</p></def></def-item><def-item><term>BID</term><def><p>twice daily</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>DAS</term><def><p>disease activity score</p></def></def-item><def-item><term>DMARD</term><def><p>disease-modifying antirheumatic drug</p></def></def-item><def-item><term>eGFR</term><def><p>estimated glomerular filtration rate</p></def></def-item><def-item><term>FAS</term><def><p>full analysis set</p></def></def-item><def-item><term>GFR</term><def><p>glomerular filtration rate</p></def></def-item><def-item><term>HAQ-DI</term><def><p>health assessment questionnaire-disability index</p></def></def-item><def-item><term>IV</term><def><p>intravenous</p></def></def-item><def-item><term>JAK</term><def><p>Janus kinase</p></def></def-item><def-item><term>LTE</term><def><p>long-term extension</p></def></def-item><def-item><term>MedDRA</term><def><p>Medical Dictionary for Regulatory Activities</p></def></def-item><def-item><term>mGFR</term><def><p>measured glomerular filtration rate</p></def></def-item><def-item><term>NSAID</term><def><p>non-steroidal anti-inflammatory drug</p></def></def-item><def-item><term>PPAS</term><def><p>per-protocol analysis set</p></def></def-item><def-item><term>Q1</term><def><p>25th percentile</p></def></def-item><def-item><term>Q3</term><def><p>75th percentile</p></def></def-item><def-item><term>RA</term><def><p>rheumatoid arthritis</p></def></def-item><def-item><term>SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term>SCr</term><def><p>serum creatinine</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>TEAE</term><def><p>treatment-emergent adverse event</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>JM Kremer and JD Isaacs are consultants for and have received research grants from Pfizer Inc. AJ Kivitz is a consultant and speaker for, and has received research grants from, Pfizer Inc. JA Simon-Campos, EL Nasonov, H Tony and S Lee have no conflicts of interest to disclose. B Vlahos, C Hammond, J Bukowski, H Li, SL Schulman, S Raber and A Zuckerman are employees of Pfizer Inc.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>BV, CH, JB, HL, SLS, SR, AZ were involved in the conception and design of the study/analyses. HL performed the data and statistical analyses. JMK, AJK, JASC, ELN, HPT, SKL and JDI were involved in data acquisition. All authors were involved in data interpretation and manuscript drafting, reviewing and development. All authors read and approved the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was sponsored by Pfizer Inc. Anne Marie Reid, PhD, of Complete Medical Communications provided editorial support funded by Pfizer Inc.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Charles-Schoeman</surname><given-names>C</given-names></name><name><surname>Wollenhaupt</surname><given-names>J</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><name><surname>Benda</surname><given-names>B</given-names></name><etal/></person-group><article-title>Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial</article-title><source>Lancet.</source><year>2013</year><volume>381</volume><fpage>451</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61424-X</pub-id><pub-id pub-id-type="pmid">23294500</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Kremer</surname><given-names>J</given-names></name><name><surname>Cush</surname><given-names>J</given-names></name><name><surname>Schulze-Koops</surname><given-names>H</given-names></name><name><surname>Connell</surname><given-names>CA</given-names></name><name><surname>Bradley</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis</article-title><source>N Engl J Med.</source><year>2012</year><volume>367</volume><fpage>495</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1109071</pub-id><pub-id pub-id-type="pmid">22873530</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>ZG</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Genovese</surname><given-names>M</given-names></name><name><surname>Martin-Mola</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tofacitinib in combination with nonbiologic DMARDs in patients with active rheumatoid arthritis: a randomized trial</article-title><source>Ann Intern Med.</source><year>2013</year><volume>159</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-159-4-201308200-00006</pub-id><pub-id pub-id-type="pmid">24026258</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Heijde</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Keystone</surname><given-names>E</given-names></name><name><surname>Kremer</surname><given-names>J</given-names></name><name><surname>Zerbini</surname><given-names>C</given-names></name><etal/></person-group><article-title>Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study</article-title><source>Arthritis Rheum.</source><year>2013</year><volume>65</volume><fpage>559</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1002/art.37816</pub-id><pub-id pub-id-type="pmid">23348607</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Garc&#x000ed;a Meijide</surname><given-names>JA</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tofacitinib or adalimumab versus placebo in rheumatoid arthritis</article-title><source>N Engl J Med.</source><year>2012</year><volume>367</volume><fpage>508</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1112072</pub-id><pub-id pub-id-type="pmid">22873531</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Fleischmann</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>B</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Gruben</surname><given-names>D</given-names></name><etal/></person-group><article-title>Tofacitinib versus methotrexate in rheumatoid arthritis</article-title><source>N Engl J Med.</source><year>2014</year><volume>370</volume><fpage>2377</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1310476</pub-id><pub-id pub-id-type="pmid">24941177</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacs</surname><given-names>J</given-names></name><name><surname>Zuckerman</surname><given-names>A</given-names></name><name><surname>Krishnaswami</surname><given-names>S</given-names></name><name><surname>Nduaka</surname><given-names>C</given-names></name><name><surname>Lan</surname><given-names>S</given-names></name><name><surname>Hutmacher</surname><given-names>M</given-names></name><etal/></person-group><article-title>Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials</article-title><source>Arthritis Res Ther.</source><year>2014</year><volume>16</volume><fpage>R158</fpage><pub-id pub-id-type="doi">10.1186/ar4673</pub-id><pub-id pub-id-type="pmid">25063045</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">European Medicines Agency CfMPfHU. European Public Assessment Report for Xeljanz, International non-proprietary name: tofacitinib. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002542/WC500154697.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002542/WC500154697.pdf</ext-link>.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">US Food and Drug Administration CfDEaR. Pharmacology review of NDA, Xeljanz (tofacitinib). <ext-link ext-link-type="uri" xlink:href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000PharmR.pdf">http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000PharmR.pdf</ext-link>.</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawendy</surname><given-names>N</given-names></name><name><surname>Krishnaswami</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Gruben</surname><given-names>D</given-names></name><name><surname>Cannon</surname><given-names>C</given-names></name><name><surname>Swan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers</article-title><source>J Clin Pharmacol.</source><year>2009</year><volume>49</volume><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1177/0091270008330982</pub-id><pub-id pub-id-type="pmid">19318693</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>N</given-names></name><name><surname>Masuda</surname><given-names>S</given-names></name><name><surname>Tanihara</surname><given-names>Y</given-names></name><name><surname>Ueo</surname><given-names>H</given-names></name><name><surname>Okuda</surname><given-names>M</given-names></name><name><surname>Katsura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1</article-title><source>Drug Metab Pharmacokinet.</source><year>2005</year><volume>20</volume><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.2133/dmpk.20.379</pub-id><pub-id pub-id-type="pmid">16272756</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klamerus</surname><given-names>KJ</given-names></name><name><surname>Alvey</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Kaplan</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2</article-title><source>Clinical Pharm in Drug Dev.</source><year>2014</year><volume>3</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1002/cpdd.120</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karstila</surname><given-names>K</given-names></name><name><surname>Harmoinen</surname><given-names>AP</given-names></name><name><surname>Lehtimaki</surname><given-names>TJ</given-names></name><name><surname>Korpela</surname><given-names>MM</given-names></name><name><surname>Mustonen</surname><given-names>JT</given-names></name><name><surname>Saha</surname><given-names>HH</given-names></name></person-group><article-title>Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance</article-title><source>Nephron Clin Pract.</source><year>2008</year><volume>108</volume><fpage>c284</fpage><lpage>c290</lpage><pub-id pub-id-type="doi">10.1159/000127362</pub-id><pub-id pub-id-type="pmid">18434750</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>RD</given-names></name><name><surname>Madias</surname><given-names>NE</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Serum creatinine as an index of renal function: new insights into old concepts</article-title><source>Clin Chem.</source><year>1992</year><volume>38</volume><fpage>1933</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">1394976</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Assessing kidney function&#x02013;measured and estimated glomerular filtration rate</article-title><source>N Engl J Med.</source><year>2006</year><volume>354</volume><fpage>2473</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1056/NEJMra054415</pub-id><pub-id pub-id-type="pmid">16760447</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Measured GFR as a confirmatory test for estimated GFR</article-title><source>J Am Soc Nephrol.</source><year>2009</year><volume>20</volume><fpage>2305</fpage><lpage>2313</lpage><pub-id pub-id-type="doi">10.1681/ASN.2009020171</pub-id><pub-id pub-id-type="pmid">19833901</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Soubrier</surname><given-names>M</given-names></name><name><surname>Antunez</surname><given-names>A</given-names></name><name><surname>Balint</surname><given-names>P</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Buch</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)</article-title><source>Ann Rheum Dis.</source><year>2014</year><volume>73</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204223</pub-id><pub-id pub-id-type="pmid">24095940</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>I</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name></person-group><article-title>The pathogenesis of rheumatoid arthritis</article-title><source>N Engl J Med.</source><year>2011</year><volume>365</volume><fpage>2205</fpage><lpage>2219</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1004965</pub-id><pub-id pub-id-type="pmid">22150039</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michaud</surname><given-names>K</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name></person-group><article-title>Comorbidities in rheumatoid arthritis</article-title><source>Best Pract Res Clin Rheumatol.</source><year>2007</year><volume>21</volume><fpage>885</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.berh.2007.06.002</pub-id><pub-id pub-id-type="pmid">17870034</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strand</surname><given-names>V</given-names></name><name><surname>Khanna</surname><given-names>D</given-names></name></person-group><article-title>The impact of rheumatoid arthritis and treatment on patients&#x02019; lives</article-title><source>Clin Exp Rheumatol.</source><year>2010</year><volume>28</volume><fpage>S32</fpage><lpage>S40</lpage><pub-id pub-id-type="pmid">20576223</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><etal/></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum.</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1002/art.1780310302</pub-id><pub-id pub-id-type="pmid">3358796</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspari</surname><given-names>F</given-names></name><name><surname>Perico</surname><given-names>N</given-names></name><name><surname>Ruggenenti</surname><given-names>P</given-names></name><name><surname>Mosconi</surname><given-names>L</given-names></name><name><surname>Amuchastegui</surname><given-names>CS</given-names></name><name><surname>Guerini</surname><given-names>E</given-names></name><etal/></person-group><article-title>Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate</article-title><source>J Am Soc Nephrol.</source><year>1995</year><volume>6</volume><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">7579093</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>GJ</given-names></name><name><surname>Work</surname><given-names>DF</given-names></name></person-group><article-title>Measurement and estimation of GFR in children and adolescents</article-title><source>Clin J Am Soc Nephrol.</source><year>2009</year><volume>4</volume><fpage>1832</fpage><lpage>1843</lpage><pub-id pub-id-type="doi">10.2215/CJN.01640309</pub-id><pub-id pub-id-type="pmid">19820136</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>SC</given-names></name><name><surname>O&#x02019;Reilly</surname><given-names>PH</given-names></name></person-group><article-title>Iohexol clearance for the determination of glomerular filtration rate in clinical practice: evidence for a new gold standard</article-title><source>J Urol.</source><year>1991</year><volume>146</volume><fpage>675</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">1875470</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erley</surname><given-names>CM</given-names></name><name><surname>Bader</surname><given-names>BD</given-names></name><name><surname>Berger</surname><given-names>ED</given-names></name><name><surname>Vochazer</surname><given-names>A</given-names></name><name><surname>Jorzik</surname><given-names>JJ</given-names></name><name><surname>Dietz</surname><given-names>K</given-names></name><etal/></person-group><article-title>Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients</article-title><source>Crit Care Med.</source><year>2001</year><volume>29</volume><fpage>1544</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1097/00003246-200108000-00008</pub-id><pub-id pub-id-type="pmid">11505124</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>B</given-names></name><name><surname>Aulie</surname><given-names>A</given-names></name><name><surname>Sveen</surname><given-names>K</given-names></name><name><surname>Andrew</surname><given-names>E</given-names></name></person-group><article-title>Human pharmacokinetics of iohexol. A new nonionic contrast medium</article-title><source>Invest Radiol</source><year>1983</year><volume>18</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1097/00004424-198303000-00015</pub-id><pub-id pub-id-type="pmid">6408018</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahn</surname><given-names>KH</given-names></name><name><surname>Heidenreich</surname><given-names>S</given-names></name><name><surname>Bruckner</surname><given-names>D</given-names></name></person-group><article-title>How to assess glomerular function and damage in humans</article-title><source>J Hypertens.</source><year>1999</year><volume>17</volume><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1097/00004872-199917030-00002</pub-id><pub-id pub-id-type="pmid">10100067</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Bansal</surname><given-names>N</given-names></name></person-group><article-title>Measured GFR as &#x0201c;gold standard&#x0201d;&#x02013;all that glitters is not gold?</article-title><source>Clin J Am Soc Nephrol.</source><year>2011</year><volume>6</volume><fpage>1813</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.2215/CJN.06040611</pub-id><pub-id pub-id-type="pmid">21784836</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincenti</surname><given-names>F</given-names></name><name><surname>Tedesco</surname><given-names>SH</given-names></name><name><surname>Busque</surname><given-names>S</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>P</given-names></name><name><surname>Friedewald</surname><given-names>J</given-names></name><name><surname>Cibrik</surname><given-names>D</given-names></name><etal/></person-group><article-title>Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1&#x000a0;year</article-title><source>Am J Transplant.</source><year>2012</year><volume>12</volume><fpage>2446</fpage><lpage>2455</lpage><pub-id pub-id-type="doi">10.1111/j.1600-6143.2012.04127.x</pub-id><pub-id pub-id-type="pmid">22682022</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspari</surname><given-names>F</given-names></name><name><surname>Perico</surname><given-names>N</given-names></name><name><surname>Matalone</surname><given-names>M</given-names></name><name><surname>Signorini</surname><given-names>O</given-names></name><name><surname>Azzollini</surname><given-names>N</given-names></name><name><surname>Mister</surname><given-names>M</given-names></name><etal/></person-group><article-title>Precision of plasma clearance of iohexol for estimation of GFR in patients with renal disease</article-title><source>J Am Soc Nephrol.</source><year>1998</year><volume>9</volume><fpage>310</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">9527409</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollenhaupt</surname><given-names>J</given-names></name><name><surname>Silverfield</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Curtis</surname><given-names>JR</given-names></name><name><surname>Wood</surname><given-names>SP</given-names></name><name><surname>Soma</surname><given-names>K</given-names></name><etal/></person-group><article-title>Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies</article-title><source>J Rheumatol.</source><year>2014</year><volume>41</volume><fpage>837</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.3899/jrheum.130683</pub-id><pub-id pub-id-type="pmid">24692527</pub-id></element-citation></ref></ref-list></back></article>